GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake

Launched by UNIVERSITY HOSPITAL, GENTOFTE, COPENHAGEN · Nov 5, 2015

Keywords

ClinConnect Summary

The gut-derived incretin glucagon-like peptide-1 (GLP-1) is a potent regulator of gastric emptying, appetite and food intake in humans whereas its sister incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), does not seem to have independent effects on these variables in humans. Interestingly, recent data from rodents have shown that concomitant activation of the GIP and the GLP-1 receptor may potentiate the satiety-promoting and body weight-reducing effects of GLP-1. Also, evidence suggests that GIP may be an important mediator of bone remodelling and lipid deposition. The ...

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Caucasian men
• • Age between 25 and 70 years
• • Body mass index (BMI) between 25 and 40 kg/m2
• Exclusion Criteria:
• • Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) ≥ 43 mmol/mol)
• • Anaemia (defined as haemoglobin \< 8.3 mmol/l)
• • Any gastrointestinal disease that may interfere with the endpoint variables
• • Anorexia, bulimia or binge eating disorder
• • Allergy or intolerance to ingredients included in the standardised meals
• • Tobacco smoking
• • Any regular drug treatment that cannot be discontinued for minimum 18 hours
• • Any physical or psychological condition that the investigator feels would interfere with trial participation